Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company’s ...

Camurus reported exceptional financial results for Q2 2025, with total revenues reaching SEK 676 million, representing a 52% increase compared to the same period in 2024. This growth was driven by ...

Find the latest Camurus AB (publ) (CAMRF) stock quote, history, news and other vital information to help you with your stock trading and investing.